Pfizer, Merck KGaA score a landmark FDA OK for checkpoint contender avelumab
Merck KGaA and Pfizer have done it.
The biopharma partners came away with their first FDA approval of the checkpoint inhibitor avelumab, making it the …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
